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ABSTRACT 
 
Background  
Induction of labour implies the artificial initiation of regular uterine contractions before the 
onset of spontaneous contractions with the purpose of achieving a vaginal delivery. 
This study aimed to compare the use of oral misoprostol and vaginal dinoprostone to 
determine differences in the labour process and the delivery methods. Maternal and fetal 
outcomes were also compared. 
 
Methods  
This is a prospective cross-sectional analytical study using medical record review at the 
Rahima Moosa Mother and Child Hospital (RMMCH) in Newclare, Johannesburg. 
This study included all women undergoing the induction process, who met inclusion criteria 
from 01 January 2016 to 30 April 2016. 
 
Results 
This study included 95 women. Forty-nine women received dinoprostone and 46 women 
received oral misoprostol. There was minimal heterogeneity between the demographics of the 
two groups. The differences in the indications for induction were statistically significant (p = 
0.001). There was no statistical difference in the time from induction to delivery (p= 0.18), 
the duration of labour (p=0.10) or in the time from induction to onset of labour (p= 0.37). 
There was a caesarean section rate of 32.7% in the dinoprostone group and 43.5% in the oral 
misoprostol group (p=0.30). There was no statistical significance between fetal and maternal 
outcomes.  
 
Conclusions 
This study yielded no difference in the labour process, time to delivery, or maternal and fetal 
complications between the two groups. Labour was initiated in more patients in the 
dinoprostone group and dinoprostone resulted in fewer c/s than misoprostol, however this was 
not statistically significant. There was no difference in neonatal and maternal outcomes. 
The use of dinoprostone or misoprostol is therefore equally effective in our setting. A larger 
study or RCT is recommended to adequately assess neonatal and maternal complication rates. 
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1 INTRODUCTION !
“It is not only that we want to bring about an easy labor, without risking injury to the mother 
or the child; we must go further. We must understand that childbirth is fundamentally a 
spiritual, as well as a physical, achievement. The birth of a child is the ultimate perfection of 
human love.” Dr. Grantly Dick-Read (1). 
 
Induction of labour (IOL) is a common procedure in obstetric practice (2). Induction of labour 
implies artificial initiation of regular uterine contractions before the onset of spontaneous 
contractions with the purpose of achieving a vaginal delivery (3, 4). Induction is thought to be 
less efficient and has an increased intensity of pain compared to spontaneous labour thus 
requiring more analgesia and resulting in more assisted deliveries (5). Induction occurs in two 
stages: cervical ripening followed by induction of uterine contractions (5). This process is also 
dependent upon the cervical status at the time of induction (5, 6). Induction of labour is 
indicated where benefits of delivery outweigh the potential harm to both mother and fetus  
(2, 3, 7). 
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2 LITERATURE REVIEW 
2.1 Prevalence  
 
In the United States of America (USA), IOL accounted for approximately 22% of all 
deliveries in 2009; more than double of that in 1990 (8). In a cross sectional study involving 
83 437 deliveries in 16 countries across Africa between 2004 and 2005, the average rate of 
IOL was 4.4% (range 1.4%-6.8%) (7). The lower rate of IOL rates in developing countries 
was thought to be due to lack of familiarity, appropriate medications, monitoring capacity, 
necessary staff in certain facilities and the lack of operating facilities in primary care centers 
to perform caesarean sections (c/s) should complications during the induction process occur. 
Due to these limitations, IOL was not routinely performed (7). In 2012, there was an increase 
in induction rates to approximately 25% in both developed and developing countries (9). This 
is due to the rise in medically and obstetrically related inductions, availability of better 
cervical agents and resources to allow induction (9).  
 
2.2 Physiology of labour 
2.2.1 The uterus 
 
During pregnancy, the uterus softens and expands to accommodate the fetus, while the cervix 
is closed to sustain the pregnancy (3). The uterus is mainly composed of smooth muscle, the 
myometrium which is pivotal in the role of uterine contractions (10). Myometrial contractions 
are brought upon by phosphorylation of actin and myosin, which is initiated by oxytocin and 
prostaglandin (PG) F2 alpha (10).  
 
2.2.2 The cervix 
 
Khan et al described the inpatient process of cervical ripening and cervical changes as a 
psychological burden for patients due to prolonged time spent in a hospital setting (11). For 
successful labour, the cervix has to become a soft and manipulative structure that can efface 
or shorten (5). Unlike the uterus, the cervix consists of collagen fibers and glycosaminoglycan 
that decrease in number allowing softening, ripening, dilatation and disarrangement of the 
collagen fibers of the cervix (3). Interleukin 8 and monocyte chemotactic protein-1 recruit 
neutrophils and monocytes for cervical ripening (5). These secrete collagenase and elastase 
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that remodel the cervix (5). Prostaglandins vasodilate cervical capillaries and increase 
permeability to neutrophils (3, 5). These promote degradation of collagen fibers, therefore 
promoting cervical softening and effacement (3, 5).  
 
2.2.3 Control pathways 
 
Increases in oxytocin production from the maternal posterior pituitary gland mediate the onset 
of contractions (3, 10). This increase production commences in the days preceding labour 
(10). With the onset of labour, there is an increase in oxytocin receptors within the uterus and 
local oxytocin production in the uterine decidua and fetal membranes (10). All these 
combined factors bring about the transition from the antenatal to the intrapartum period. 
 
2.3 History  
 
Hippocrates first described IOL with stimulation of the mammary glands and mechanical 
dilatation of the cervix (12, 13). Induction of labour was initially used to deliver intrauterine 
fetal deaths (IUFD) as an attempt to expedite delivery in order to reduce the threat to maternal 
health (14). From the second to the seventeenth century, mechanical methods together with 
homeopathic medications were commonly used (13). In the early twentieth century, 
observations were made that the extracts from the posterior pituitary gland caused uterine 
contractions, but with side effects (13). Theobald described intramuscular, subcutaneous and 
then intravenous infusion of oxytocin in 1949 (13). Prostaglandins were first described in the 
1960s for IOL and most recently misoprostol has been accepted as a safe measure for IOL 
(13). 
 
 
 
 !!
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2.4 Methods of induction of labour 
2.4.1 Mechanical methods 
 
Mechanical methods included uterine bougies, stomach tubes, De Ribe’s bag, forced rapid 
dilatation of the cervix and vaginal c/s (15). In 1942 amniotomy became the method of choice 
and in 1955 it was used together with other mechanical methods (15). A Cochrane review by 
Jozwiak et al, on mechanical methods included 9 722 women (16). Methods included 
laminaria tents, balloon catheters and extra amniotic fluid infusion. Advantages were reduced 
costs compared to hormonal methods, decrease side effects, decreased hyperstimulation and 
easier storage (16). Mechanical methods compared to hormonal methods did not decrease the 
c/s rate or the number of women who delivered within 24 hours (16).  
 
2.4.2 Alternative/ Complementary medicine 
 
Castor oil, seed of the plant Ricinus Communis, was used for IOL in the 1930s but was 
abandoned by 1961 due to its’ propensity to produce severe diarrhoea (15). A Cochrane 
review was inconclusive about the effectiveness but supported the high side effect profile 
(17). There is also a possibility of castor oil causing teratogenic effects similar to ‘ fetal 
hydantoin syndrome’; a syndrome related to the use of epileptic drugs associated with 
intrauterine growth restriction, cranial and limb deformities (18). 
 
Acupuncture is one of the oldest methods described and is a safe procedure (19). In a double-
blinded randomized control trial (RCT) by Modlock et al; 125 women with post term 
pregnancies were randomized to either acupuncture or “sham” acupuncture (19). “Sham” 
acupuncture was the use of a needle where the needle retracted and did not penetrate the skin 
compared to the needle in the acupuncture group that did penetrate the skin (19). This showed 
no effect of acupuncture on induction (19).  
 
Hypnosis is a relaxation technique, which was commonly used to calm a labouring woman 
(20). There have been no RCT’s describing the benefits or risks of hypnosis and this needs to 
be studied further (20). It is postulated that hypnosis may delay standard care and should be 
individualized (20).  
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Breast stimulation, membrane sweeping and sexual intercourse have also been described. 
Breast stimulation is thought to trigger the release of oxytocin and membrane sweeping 
increases PG production (21, 22). Sexual intercourse was thought to have been an alternative 
method to IOL as semen contains PGs, but this was shown to be ineffective (21, 22).  
 
2.4.3 Pharmacological methods 
 
Vaginal isosorbide mononitrate is a nitric oxide donor, used mainly for patients with angina 
pectoris (23). Nitric oxide synthase isoforms increase in the cervix preceding labour hence 
thought that nitric oxide donors could be used as cervical ripening agents (23). Compared to 
placebo, vaginal isosorbide mononitrate showed no difference in labour outcome, c/s rate or 
neonatal outcomes (24). It had a high side effect profile causing severe headaches (24). 
  
Hyaluronidase in an injectable form was thought to increase cervical ripening as hyaluronic 
acid increased the tissue water content (25). This drug when compared to a placebo showed a 
decrease in c/s rate, decrease use of oxytocin for augmentation and increased cervical 
favourability after 24 hours with no maternal or neonatal adverse outcomes (25). This method 
was considered invasive and less invasive methods were preferred (25). 
 
Oxytocin is a hormone produced by the maternal posterior pituitary gland and stimulates 
uterine contractions during labour (3, 10, 21). Initially oxytocin was used on its own but in 
1990 it was to have better effects on labour outcomes as an adjunct to PGs or with amniotomy 
(15). 
 
Oestrogen, in the form of teratogenic Stilboestrol or Hexoestrol, was first described in 1942 
mainly for patients’ with an IUFD or for medical termination of pregnancy (21, 24). It was 
primarily used in these patients, as there was no concern for neonatal outcomes in large doses. 
When compared to placebo, oestrogen showed no difference in labour or delivery outcomes 
(24).  
 
Corticosteroids have also been suggested as induction agents but studies remain inconclusive 
about their effectiveness in inducing labour (26). 
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Relaxin is a protein hormone produced by the corpus luteum (27). Kelly et al, in a systematic 
review of four studies including 267 women showed no difference in c/s rate when relaxin 
was compared to placebo (15.3% vs 14.2%) (27). Further studies are needed to evaluate the 
full effects of relaxin. 
 
Mifepristone is an oral antiprogestin that has a recognized role in first and second trimester 
medical termination of pregnancy (28). It has been studied as an inducing agent in the third 
trimester (28). In a Cochrane systematic review by Hapangama and Neilson, ten trials 
including 1 108 women, compared mifepristone to placebo (28). Those induced with 
mifepristone were more likely to achieve labour after 48 hours of induction, had a decrease 
need for oxytocin augmentation, a decreased rate of c/s but an increased rate of assisted 
delivery. Different doses ranging from 50mg to 600mg were studied with the lowest effective 
dose being 200mg for cervical ripening (28). Fetal heart rate changes were observed with 
mifepristone but no differences in neonatal outcomes (28). Even though mifepristone may be 
an effective inducing agent, it is costly and not readily available in the government setting in 
South Africa (SA). 
 
2.5 Maternal characteristics 
 
Induction of labour is indicated where the risks to continue the pregnancy outweigh the 
benefits (9, 12). Factors that influence the risk: benefit ratio includes gestational age (GA), 
fetal lung maturity, clinical condition, cervical factors and demographics (9). 
 
2.5.1 Parity 
 
Parity is defined as the number of previous viable pregnancies where viability is specific to a 
country or institute (3). Nulliparous women were thought to have a higher rate of c/s, 
however, studies that concluded this included patients with medical conditions and 
unfavourable cervices, hence a bias (29). In an analytical study by Levine et al, both 
nulliparous and multiparous women had a increased c/s rate when induced compared to 
spontaneous labour (29). Nulliparous women were likely to have a prolonged first stage of 
labour compared to multiparous women who have a prolonged second stage of labour 
(p=0.04). Multiparous women had a higher rate of vaginal delivery than nulliparous women 
(97% vs 80%,p < 0.001) (29).  Ivars et al showed that modifying the Bishop’s score to include 
! 7!
parity, significantly improved the prediction of success of IOL (30). This implies that parity 
plays an important role in successful induction (29, 30).  
 
2.5.2 Obesity 
 
The World Health Organization (WHO) defines overweight as a body mass index (BMI) of 
greater than 25 kg/m2 and obesity as a BMI of more than 30 kg/m2 (31). In SA, 40% of 
women are obese (32). According to the Saving Mothers report from 2014-2016, obesity was 
associated with the increased risk of thrombosis, diabetes, macrosomic babies (>4000g), 
difficult c/s, postpartum haemorrhage (PPH) and post c/s sepsis (33).  
 
A prospective study by Vinturache et al, including 1 996 women, showed that obesity 
increased the rate of IOL with no difference in induction method; 49% of obese women had 
IOL (34). These were attributed to obese women having more increased pregnancy-related 
complications such as pre-eclampsia, macrosomia and diabetes (34). Obese women had a 
significantly higher c/s rate compared to normal weight women (21.1% vs 11.2%) (34). There 
was no difference in the duration of labour. Obesity contributed to the increased rates of IOL, 
poor progress in labour, increased c/s rates, augmentation and increased PPH (34).  
 
This differed in a study by Arrowsmith et al where PPH rates were similar in all BMI 
categories but agreed that obesity resulted in an increased c/s rate (35).  
 
2.5.3 Indications for induction of labour 
2.5.3.1 Post term pregnancy 
 
According to the WHO and The American College of Obstetricians and Gynecologists 
(ACOG), post term pregnancy is defined as a pregnancy extending beyond 294 days or 42 
weeks measured from the last normal menstrual period (8, 36). This is known as Naegele’s 
rule (8, 37). Post term pregnancy is the most common indication for IOL (8, 37, 38). 
Globally, the prevalence of post term birth is 5 to 10% and varies between countries with 
some studies stating an incidence of 4 to 22% (39-41). Arrowsmith et al in the United 
Kingdom (UK) showed that the incidence of post term pregnancy is 22.3% (35). In the United 
States of America (USA) the incidence of post term pregnancy is approximately 7% (40). 
Risk factors included advanced maternal age, Caucasian, obesity and primigravidas (41). In 
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Pakistan the incidence is quoted at 21% (39). Arif et al explained risk factors such as obesity, 
excess fish consumption and a male fetus contributed to post term pregnancy (39). In New 
South Wales the incidence of post term pregnancy is 13% (39, 41). Dekker et al attributed this 
low incidence in New South Wales to patients being induced earlier than 41 weeks gestation 
(41).  
 
Management of IOL during pregnancy relies on accurate estimation of gestational age (42).  
Methods for determining GA include the last normal menstrual period (LNMP), clinical 
assessment of the symphysis-fundal height and ultrasound biometry (42). The use of LNMP 
for dating the pregnancy may have many faults owing to incorrect recall of dates, irregularity 
of the menstrual cycle, anovulatory cycles and confusion in whether an atypical light bleed 
may be menstruation or not (43).  
 
Developed countries have shown a lower incidence of post term pregnancies compared to 
developing countries (7% vs 10-16%) due to the accessibility of early ultrasound (ultrasound 
before 23 weeks) and accurate dating (40, 44). A study in Tygerberg, Western Cape South 
Africa, showed that routine ultrasound between 18-23 weeks GA reduced their incidence of 
preterm pregnancies from 16.7% to 12%, and post term pregnancies from 10.8% to 8.1% 
(45). This was also proven by a similar follow up study at Tygerberg Hospital comparing 
different dating methods (42). This study at Tygerberg Hospital comparing different dating 
methods showed that only 56% of women were sure of their LNMP and the LNMP was only 
concordant with ultrasound between 18-23 weeks GA in 35.6% of patients. It also showed 
that the incidence of preterm and post term pregnancies (4.7% to 1.6%) was significantly 
decreased in those that had an early ultrasound. Differences in the actual date of delivery and 
expected date of delivery were largest when the LNMP was used (42). Ultrasound improved 
the accuracy of the date of delivery from 27% to 42% compared to clinical measurement of 
the symphysis-fundal height and LNMP. This study concluded that in a low resource setting 
where patients book late (after 23 weeks), dating with ultrasound is better for estimating GA 
compared to LNMP and clinical methods (42). A RCT done in Johannesburg also showed a 
lower rate of IOL in those who had ultrasound between 18-23 weeks (1.6%) versus the 
control (3.6%) (46). 
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The concept of inducing post term pregnancies owes to the increased risk of perinatal 
morbidity and mortality (41). Yudkin proved this finding in an exponential curve of stillbirths 
(Figure 2.1), which showed that the stillbirth rate is at a low point towards the beginning of 
the term period and then rises thereafter (41, 47). In a prospective cohort in New York City 
over a three year period (1987-1989) including 2 454 stillbirths, the incidence of stillbirths 
increased progressively after 40 weeks gestation (38). The incidence was 2.11 per 1000 live 
births at 40 weeks and 2.66 per 1000 live births at 43 weeks (38). Other studies have shown 
the risk of stillbirths at 42 weeks to range from 1.55 to 4.36 per 1000 live births in the 1980s 
and 1990s (41). A better understanding of IOL led to a reduction in stillbirth rates in the 
2000s, 0.6 to 1.17 per 1000 live births (41).  
 
 
 
Figure 2.1 Yudkin’s curve of stillbirths per 1000 undelivered fetuses for two weekly  
      gestational age  
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Other fetal complications of post term pregnancy included macrosomia, shoulder dystocia and 
neurological sequelae (48). Maternal complications include abnormal labour, failed induction, 
perineal lacerations, sepsis and PPH (48).  
 
Due to these risks and complications, IOL is recommended between 41 and 42 weeks 
gestational age for healthy women with no associated comorbidities (41, 48). There is 
currently a RCT underway, the Swedish Post-Term Induction Study (SWEPIS), that aims to 
establish if IOL at 41 weeks is superior to IOL at 42 weeks (37). This study aims to 
randomize women across various hospitals in Sweden (with 65 000 deliveries per annum) to 
either IOL at 41 weeks or expectant management and induction at 42 weeks. According to the 
protocol of SWEPIS, larger randomized trials are needed for a definitive answer on induction 
in post term pregnancies since most studies on post-term pregnancies are observational (37). 
The SWEPIS study will compare neonatal morbidity and mortality in this regard. The study 
will be completed in August 2018.  
 
Women who decline IOL after 42 weeks should have counseling, twice-weekly fetal non-
stress test (NST) monitoring, amniotic fluid index (AFI) measurements or a fetal biophysical 
profile (2, 4). 
 
2.5.3.2 Prelabour rupture of membranes  
 
Term prelabour rupture of membranes (PROM) occurs in 8 to 10% of pregnant women (49). 
Spontaneous onset of labour within 12 hours occurs in 79% of women and 95% within 24 
hours regardless of cervical favourability (50). Delayed or prolonged labour can occur in 
those that do not spontaneously labour within 7 days after PROM (50).  
 
Prelabour rupture of membranes is associated with increased maternal and fetal sepsis, 
umbilical cord compression, and placental abruption; thus, active management is preferred in 
patients with PROM provided that the benefits of delivery outweigh the risks of prematurity 
(50-52).  
 
A Cochrane review of 12 trials including 7 000 women showed that active management did 
not increase the c/s rate or rate of vaginal births, but decreased the rate of chorioamnionitis 
and endometritis (50).  The largest trial used in the Cochrane review was by Hannah et al 
(52). The Term PROM study, a double-blinded RCT including 5 041 women, compared 
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expectant to active management. Active management was immediate IOL with oxytocin or 
prostaglandin E2 (PGE2) gel and expectant management was IOL after 4 days of PROM (52). 
There was no difference in c/s rate or rate of neonatal sepsis (52). The rates of 
chorioamnionitis were reduced with oxytocin. Women also preferred a quicker birth time 
from rupture of membranes (52). The National Institute for Health and Care Excellence 
(NICE) guidelines recommend IOL 24 hours after PROM due to increased risks of 
chorioamnionitis (2).  
 
Colonization by Group B streptococcus (GBS), Streptococcus Agalactiae, occurs in 10 to 
30% of pregnant women (53). GBS is a major cause of neonatal morbidity and mortality. The 
USA recommends universal screening of GBS between 35 and 37 weeks gestational age with 
rectovaginal swab specimens and treatment with penicillin (53). This has not yet been 
implemented in SA as it is not economically viable and there are no studies that address that 
screening for GBS has any impact on neonatal morbidity and mortality (54).  Prolonged 
rupture of membranes and intra-amniotic infection in women colonized with GBS are among 
the risk factors of early neonatal GBS infection (53).  
 
A prospective study in Australia included 574 women with PROM and induced only women 
who were GBS polymerase chain reaction (PCR) positive (55). Those that were PCR negative 
were managed as outpatients, with 80.6% of these women either going into spontaneous 
labour or being induced within 72 hours. There were no cases of neonatal GBS infection, 
maternal chorioamnionitis or postpartum endometritis in mothers who were GBC PCR 
positive (55). A protocol for GBS screening is yet to be implemented in SA provincial and 
academic hospitals. There is a study at Chris Hani Baragwanath Academic Hospital in 
Soweto, Gauteng that is currently in progress to assess the incidence of GBS within the 
population and neonatal and maternal outcomes.  
 
Commonly used drugs in PROM include oral misoprostol, vaginal dinoprostone and oxytocin 
(52). A RCT in the United Kingdom (UK), including 758 women with PROM, showed that 
low dose oral misoprostol has better outcomes than vaginal dinoprostone (56). Misoprostol 
induction required less use of oxytocin, less need for epidural analgesia and decreased the rate 
of c/s for poor progress. There were higher rates of uterine hyperstimulation and tachysystole 
compared to dinoprostone (56, 57). Another study showed that misoprostol, compared to 
dinoprostone, resulted in more vaginal deliveries within 12 hours and a shorter induction-to-
delivery interval (58).   
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Oral routes of misoprostol were preferred over vaginal routes of dinoprostone due to the 
following factors (56, 58): 
• Easy administration 
• Avoided frequent vaginal examinations 
• Allowed easy mobilization of the mother  
• Lowered the risk of maternal and neonatal sepsis  
• Better efficacy than a vaginal drug as the vaginal drugs could be expelled with the 
draining of amniotic fluid.  
 
2.5.3.3 Hypertension in pregnancy 
 
Hypertension (HT) is one of the leading causes of maternal deaths accounting for 14.77% of 
maternal deaths in SA (33). Due to this, IOL has been an option for management of patients 
with gestational hypertension or pre-eclampsia. This is to prevent severe maternal and 
neonatal complications such as HELLP (Hypertension, Elevated Liver enzymes, Low 
Platelets) syndrome, placental abruption, maternal death and neonatal asphyxia (59).  
 
A RCT, the Hypertension and Pre-eclampsia Intervention Trial At Term (HYPITAT), was 
published in 2009, including 756 patients that compared expectant to active management in 
hypertensive women at term (59). It showed that IOL decreased poor maternal outcomes and 
progression of the disease (RR 0.71, p <0.0001). The induction group had a decreased c/s 
rate, although this was not statistically significant (RR 0.75, p <0.085). There were no 
differences in neonatal outcomes. 
 
Intrauterine growth restriction (IUGR) is one of the complications of HT in pregnancy and 
this led to the Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT); a 
RCT comparing expectant to active management in 650 patients with HT and suspected 
IUGR (60). The trial showed no difference in adverse neonatal outcomes, rates of c/s or 
assisted delivery. It did support the HYPITAT trial that IOL decreased the progression of 
gestational HT to pre-eclampsia (p <0.005). Therefore, IOL is supported in IUGR fetuses to 
possibly decrease the incidence of IUFD (60). 
 !
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2.5.3.4 Diabetes in pregnancy  
 
Gestational diabetes mellitus (GDM) has been increasing in prevalence with the increase in 
obesity (61). Gestational diabetes mellitus increases the risk of macrosomia, birth 
complications, IUFD at term and pre-eclampsia (61, 62). Timing of delivery is crucial in 
women with GDM due to neonatal morbidity and mortality (62). The Hyperglycaemia and 
Adverse Pregnancy Outcomes (HAPO) study showed the higher the glucose levels, the higher 
the frequency of large for gestational age fetuses, which may lead to macrosomic babies (63). 
Macrosomia is associated with shoulder dystocia and an increased risk of c/s (64).  Infants of 
mothers who have GDM are also subjected to neonatal hypoglycaemia (63).  
 
The timing of delivery is dependent on the risk of neonatal morbidity and mortality versus the 
increased risk of stillbirths (62). It is recommended that women with pregestational diabetes 
be delivered at 39 completed weeks gestational age with confirmation of fetal lung maturity, 
although this should be individualized (62). Women with GDM controlled on diet and 
exercise should be delivered between 40 and 41 weeks and if they are on treatment delivery is 
recommended at 39 completed weeks (62). Inducing labour is beneficial than expectant 
management in women with GDM and decrease the c/s rate (62). 
 
Other indications for IOL include(2, 4, 8): 
• Oligohydramnios 
• Chorioamnionitis 
• Intrauterine fetal death (IUFD) 
• Fetal malformations incompatible with life 
 
2.5.4 Contraindications to induction of labour 
 
Induction of labour is contraindicated where risks of labour and vaginal delivery outweigh the 
risks of c/s (9). Patients with a prior lower segment c/s scar are at increased risk of uterine 
rupture with complications such as PPH, hysterectomy, urinary tract injury and neonatal 
morbidity and mortality (65). Obstetric haemorrhage is one of the leading causes of maternal 
mortality in South Africa and accounted for 15.79% of maternal deaths between 2011 and 
2013 (33). Of these 7.6% were due to uterine rupture with previous c/s scar and 32.3% due to 
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bleeding during and after the c/s (33).  The risk of uterine rupture increases with PG use and 
is seen with the use of misoprostol (65, 66).  
 
In a large retrospective cohort study, IOL with PGs in women with a previous c/s scar led to 
an increased risk of 24.5 per 1000 women of uterine rupture (67). In comparison to elective 
repeat c/s, IOL with PGs increase the risk of uterine rupture 15 fold (RR 15.6) and this was 
also found in a population-based study in Norway (66, 67). Patients with a previous c/s scar 
that desire a trial of labour are high risk and should be monitored vigilantly (66). According to 
the Society of Obstetricians and Gynaecologists of Canada (SOGC), these women should be 
in a hospital where theatre facilities are readily available and should an emergency c/s be 
warranted, this should be achieved within 30 minutes (68). Intrapartum, continuous fetal 
monitoring is required along side careful examination and monitoring for uterine rupture (68).   
 
Due to this risk of uterine rupture, previous lower segment c/s scar at term is a relative 
contraindication to IOL (68). Patients with a previous c/s scar in a low resource setting like 
RMMCH are not induced, as we do not readily have the facilities to monitor these patients or 
guarantee that an emergency c/s can be performed within 30 minutes. 
 
Other contraindications to IOL include (8, 9, 69): 
• Placenta praevia major (due to the increased risk of antepartum haemorrhage and 
PPH) 
• Transverse fetal lie 
• Invasive cervical carcinoma 
• Cord presentation/prolapse 
• Active genital herpes 
• Fetal distress 
 !!
 !!
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2.6 Labour findings 
2.6.1 The role of the Bishop score 
 
Cervical status is a determinant factor in the success of induction (9). The modified Bishop 
score is a cervical assessment system that determines the likelihood of a vaginal delivery (9). 
It was originally described in multiparous women (70). Components of the Bishop score 
include cervical dilatation, effacement, consistency, position and station of the presenting part 
(70). The higher the Bishop score, the higher the likelihood of spontaneous or induced vaginal 
delivery (9). A simplified scoring system is currently being studied using three factors: 
dilatation, station and effacement. It has shown to have a better positive and negative 
predictive value and positive likelihood ratio compared to the Bishop score using five 
components (70). 
 
Prior to the introduction of cervical ripening agents, a low Bishop score was associated with 
failed induction, prolonged labour and increase c/s rate (71). A large study by Johnson et al 
comprising 7 282 deliveries showed that patients induced with scores less than five had an 
increase c/s rate (72). 
 
There is controversy about intra- and interobserver differences, as assessing the cervical status 
is subjective (73). Transvaginal ultrasound is an objective way to assess the cervical status 
(73). In a prospective study of 340 women, the parameters of transvaginal ultrasound had a 
95.5% sensitivity and 84.6% specificity compared to the Bishop score which had a 65.3% 
sensitivity and 80.8% specificity (73). This was a small study. A larger systematic review by 
Verhoeven et al that included 5 029 women compared the transvaginal ultrasound to the 
Bishop score and showed no difference in its ability to predict successful induction (74). 
 
An analysis of the HYPITAT and DIGITAT trial showed no difference in c/s rate or adverse 
neonatal outcome in women induced with a Bishop score less than six compared to expectant 
management (75). Hence a Bishop score of less than six indicates an unfavourable cervix and 
a score of greater than eight increases the probability of a normal vaginal delivery (8, 9). 
Methods for cervical ripening are therefore needed to induce labour (76). 
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2.6.2 Dinoprostone 
 
Dinoprostone is a synthetic PGE2 analogue, used for IOL since the 1960s (77). It is available 
in cervical gel, vaginal insert or tablet forms and is approved by the Food and Drug 
administration for cervical ripening in women at or near term (8, 70, 77).  It has a half-life of 
four to seven hours (78). Between 12-28% is absorbed into the circulation (78). Maximum 
plasma levels are reached within two to three hours and the drug is still detectable six to eight 
hours after administration (78).  Recommendations for the use of the gel form are six hourly 
with a cumulative dose of 1.5mg /24 hours (8, 78). Side effects of PGs include pyrexia, 
thermoregulatory effects on the brain, diarrhoea and nausea (12). 
 
Advantages include (78, 79): 
• Safety of administration 
• Greater bioavailability with a quicker release and absorption 
• Predictable clinical response 
 
Disadvantages include (78, 80): 
• Frequent vaginal examinations (six hourly) 
• Unstable at room temperature, therefore, requires refrigeration 
• Unclear evidence regarding intervals of NST monitoring 
 
In a Cochrane review by Thomas et al, 70 RCT’s including 11 487 women, compared vaginal 
dinoprostone to other methods of IOL (77). 
• Compared to placebo, dinoprostone resulted in more women delivering within 24 
hours (12% vs 0%, RR 0.12). There was marked heterogeneity within the studies and 
accounting for all of these differences there was no statistical significance in delivery 
rate between dinoprostone and placebo. There was a decreased c/s rate with 
dinoprostone of approximately 10%. There were significantly higher rates of uterine 
hyperstimulation compared to placebo (RR 3.16). 
• Low dose vaginal dinoprostone (<3mg) compared to high dose vaginal dinoprostone 
showed that there was no difference in c/s rate even though low dose vaginal 
dinoprostone was associated with less uterine hyperstimulation and with less fetal 
heart rate changes. 
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2.6.3 Misoprostol 
 
Prostaglandins are a group of cyclopentane derivatives (hydrogel polymers) of arachidonic 
acid (70). Misoprostol is a synthetic PGE1 analogue available in tablet forms. Initially 
misoprostol was used for gastric protection against the effects of non-steroidal anti-
inflammatories. In 2002 the Food and Drug Administration approved the use of misoprostol 
for IOL and cervical ripening (vaginally, orally and sublingually) (8, 70). It imitates the 
cervical changes of natural PGs by increasing the absorption of water and softening the cervix 
(70). It also acts directly on the myocytes of the uterus to increase uterine contractility (70). 
 
Misoprostol has a half-life of 20-40 min after oral administration with peak serum 
concentrations at 30 min and rapid decline by 120 minutes (81). Eighty percent of the drug is 
excreted by the kidneys (70). Different dosages have been used across the globe ranging from 
25ug to 200ug (82).  
 
Advantages include (6, 82): 
• Inexpensive 
• Easily stored at room temperature 
• Non- invasive administration in the oral form 
• Few systemic side effects 
 
Disadvantages include (79, 82): 
• Diarrhoea and nausea (dose-dependent) 
• Pyrexia 
• Difficulty in dosing due to the tablet form 
• Inability to discontinue misoprostol effects 
• Uterine hyperstimulation and tachysystole 
• Teratogenic effects 
 
The teratogenic effects of misoprostol include extremities of the fetus (club foot, agenesis of 
the hands and feet, syndactyly and constriction rings) (82). Mobius sequence was also 
identified in these fetuses, which is the loss of motor function of the cranial nerves (82). 
These effects were identified when misoprostol was used in the first trimester for termination 
of pregnancy (82).  
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In a Cochrane review by Alfirevic et al, 76 trials including 14 412 women, oral misoprostol 
was compared to other methods of IOL (82).  
• Compared to placebo (1 109 women), misoprostol resulted in more women delivering 
vaginally within 24 hours (RR 0.16), less use of oxytocin and a decrease in c/s rate. 
• Compared to oxytocin alone (1 282 women), misoprostol resulted in a decreased c/s 
rate (RR 0.88) but had a slower induction time.  
• Compared to vaginal dinoprostone (3 859 women), misoprostol resulted in 
significantly decreased c/s rate (RR 0.88) but no difference in women who achieved 
vaginal delivery within 24 hours (RR 0.78). There were no differences in rates of 
hyperstimulation.   
 
2.6.4 Analgesia during labour 
 
“ There is no other circumstance in which it is considered acceptable for an individual to 
experience untreated severe pain that is amenable to safe intervention while the individual is 
under a physician’s care.” (83) 
 
The early first stage of labour is more visceral in nature and diffuse as opposed to the late first 
stage and second stage where the pain is somatic and localized in nature (83). The type of 
labour influences the need for pain relief: spontaneous or induced labour (84). Non-
pharmacological methods include relaxation techniques, distraction techniques, acupuncture, 
reflexology, aromatherapy, nerve stimulation and sterile water injection (84). 
Pharmacological methods include nitrous oxide inhalation, opioids and regional anaesthesia 
(84).  
 
Opioids continue to be used for intrapartum analgesia as they are cost-effective and require no 
specialized skills (83). Opioids have little effect on maternal pain scores and cause nausea and 
vomiting (83). Morphine, fentanyl, pethidine and remifentanil are the most commonly used 
opioids (83). All opioids cross the uteroplacental barrier and cause neonatal respiratory 
depression (83). 
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Epidural analgesia is a central nerve blockade technique that blocks pain impulses (85). 
Advantages include (83, 85):  
• Pain relief with motor function spared 
• Allows the patient to remain alert 
• Continuing pain relief throughout the duration of labour 
• Avoids neonatal respiratory depression caused by opioids 
 
Disadvantages include (83, 85): 
• Non-uniform spread of anaesthesia 
• Hypotension (if significant may cause uteroplacental insufficiency) 
• Pyrexia 
• Urinary retention 
• Post dural puncture headache  
• Itchiness, drowsiness, shivering 
 
In a retrospective case series by Antonakou and Papoutsis, epidural analgesia in all women 
induced was studied (85). The rate of epidural analgesia was 31.2% with a higher assisted 
delivery rate than c/s rate (23.1% vs 15.1%). The most common indication for c/s was poor 
progress followed by fetal distress. The c/s rate was not increased by epidural analgesia but by 
increased birth weight and prolonged second stage of labour. Inducing labour with epidural 
analgesia had no significant increase in oxytocin use or overall prolonged labour (85).  
Bannister-Tyrrel et al, in a population based cohort study in Australia, found an epidural rate 
of 31.5% and epidural analgesia was associated with an increase in c/s rate with a RR of 2.5 
(86). Somuah et al in a Cochrane review also concluded that epidurals were associated with a 
higher rate of assisted delivery (RR 1.42), prolonged second stage of labour (mean difference 
13.66 minutes, 95% CI 6.67 to 20.66), increased augmentation with oxytocin (RR 1.19) and 
increase c/s for fetal distress (RR 1.43) but no overall increase in c/s rate (84).  
One study by Ivars et al showed a higher rate of epidural analgesia of 88%. This was a study 
done in France to compare parity and the Bishop score, however no further elaboration was 
made on the epidural rate (30). 
The RESPITE trial (Remifentanil intravenously administered patient-controlled analgesia 
(PCA) versus pethidine intramuscular injection for pain relief in labour) by Wilson et al is 
currently in progress and aims to compare intravenous remifentanil to intramuscular pethidine 
in a RCT (87). The primary aim is to measure how many women still required an epidural 
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despite being given remifentanil or pethidine. This study would be useful in an alternative 
method to epidurals that would be cost-effective and easy to administer (87).  
2.7 Delivery methods 
2.7.1 Caesarean section rates and normal vaginal delivery rates 
 
Caesarean section increases maternal mortality and morbidity, prolongs postpartum maternal 
recovery, and increases placental complications in subsequent pregnancies due to the uterine 
scar (88). It also causes difficulty in establishing breastfeeding, increases neonatal morbidity 
and mortality, and increases the cost to the health care system (88).  
 
Davey et al included 42 950 births in a cross sectional analysis of c/s following IOL (88). 
Spontaneous labour occurred in 46.8% of patients and 9.7% of patients were induced. There 
was an increase in the c/s rate with IOL (p <0.001) (88). 
 
Alfirevic et al showed that misoprostol had a decrease c/s rate compared to dinoprostone (82, 
89). However these reviews were based on studies that all used different doses of oral 
misoprostol ranging from 20ug to 200ug. The most effective dose was shown to be 20ug to 
25ug of oral misoprostol as it reduced side effects (82). Alfirevic et al also grouped studies 
into oral misoprostol doses of less than or more than 50ug. He showed that doses less than 
50ug resulted in a decreased c/s rate (89).  
 
A large randomized clinical trial (comprising 695 women) in 2001, done at RMMCH and 
Liverpool Women’s Hospital by Hofmeyr et al, showed no difference in time to achieve 
vaginal delivery or c/s rates between dinoprostone and misoprostol (90).  Rates of maternal 
and fetal outcomes were also similar. In this study, high doses of oral misoprostol (20ug for 
the first two or three doses and then 40ug thereafter until adequate uterine contractions were 
achieved or a maximum period of 12 hours) and high doses of dinoprostone (two milligrams 
six hourly) were used. 
 
Matonhodze et al performed a similar study to Hofmeyr et al in 2003 (79). The study included 
171 women in the three academic hospitals in Johannesburg, SA: RMMCH, Charlotte 
Maxeke Academic hospital and Chris Hani Baragwanath Academic hospital (79). There was 
no difference in time to delivery within 24 hours between the two drugs, however there was 
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an increased c/s rate in the dinoprostone group (24% vs. 14%, RR 0.85). No difference in 
maternal and fetal outcome between the two groups. 
 
In a study in KwaZulu-Natal (KZN) in 2003 by Moodley et al, 396 women were randomized 
to receive either misoprostol or dinoprostone (91). This study used 20ug at two hourly 
intervals of oral misoprostol (until adequate uterine contractions achieved or a maximum of 
80ug) and one milligram six hourly of dinoprostone (up to three doses). No difference in 
delivery rate within 24hours or c/s rate was found. There was an increased number of c/s for 
fetal distress in the oral misoprostol group. There were no differences in maternal or fetal 
outcomes between the two groups.  
 
A more recent study in a regional hospital in KZN by Malende et al included 502 women who 
were induced (92). Inducing agents compared were oral misoprostol and vaginal misoprostol. 
This study included IUFDs and used vaginal misoprostol with doses ranging from 50-100ug.  
The overall c/s rate was 40.2%. The overall rate of NVD within 24 hours was 69.7%. They 
also found that 9.4% of patients required a second cycle of induction and 2.4% a third cycle. 
Oral misoprostol resulted in more patients requiring another cycle of induction. Neonatal 
complications were reported in 1.8% of patients; these neonates required neonatal intensive 
care unit (NICU) admission and there was one reported early neonatal death. There was a 
delay from the time of booking the c/s to the patient getting to a theatre. There were no 
adverse maternal outcomes (92).  
 
Some of the above studies were done in a similar setting to our own. Differing results were 
obtained; this may be the result of different doses used in the studies. !
2.7.2 Time to caesarean section 
 
The interval between decision for emergency c/s to delivery should be no more than 30 
minutes (93). In a prospective study by MacKenzie and Cook, deliveries of 415 women were 
analyzed according to emergency or non-urgent cases. Outcomes were measured by arterial 
cord blood pH. The mean time from decision to delivery in emergency cases was 42.9 
minutes and 71.1 minutes in non-urgent cases (93). The average cord blood pH in the 
emergency group was 7.20 and 7.24 in the non-urgent cases, which was statistically 
significant. In most cases, the urgency for the c/s was fetal distress(93). There was no 
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evidence in this study that a c/s within 30 minutes from decision to delivery would improve 
neonatal mortality (93). 
 
In 2011, NICE published guidelines that recommended a 30-minute decision to delivery time 
when there is an immediate life threatening condition to the fetus or mother (94). This could 
be extended to 75 minutes when there is compromise to either mother or fetus that is not life 
threatening (94). It is also stated that these guidelines should take into account the team 
performance for each individual c/s. Limited resources or constraints on the health care 
personnel may influence this; the healthcare personnel may be occupied with more life 
threatening cases, therefore, a particular c/s may not be done in the acceptable time frame (94, 
95).  
 
2.8 Neonatal outcomes 
 
Neonatal outcomes are measured by NICU admission, the Apgar score at 5 minutes and 
incidence of neonatal death (82, 90).  
 
Misoprostol showed that more fetuses developed meconium stained liquor when compared to 
placebo, oxytocin or dinoprostone but overall had no effect on neonatal outcomes (82). When 
dinoprostone was compared to placebo, there were no differences in neonatal outcome (89).  
 
Neonatal respiratory distress syndrome (RDS) is defined clinically as either an abnormality in 
respiratory rate, labored breathing or the presence of cyanosis (96). Transient tachypnea of the 
newborn (TTN) is defined as the acute onset of RDS that improves within a few hours from 
birth and completely resolves in 24 to 48 hours (96). A retrospective study by Tochie et al in 
Cameroon found that neonates with Apgar <7 at 1 minute, male gender, birth weight >4000g 
and prematurity were independent risk factors for RDS (96). Maternal fever and 
chorioamnionitis were not associated with RDS due to the use of antibiotics and possibly due 
to the thought that PROM activates an inflammatory cascade that accelerated fetal lung 
maturity (96). Tochie et al showed that neonatal infections, TTN, hyaline membrane disease 
and meconium aspiration syndrome (MAS) were the main causes of RDS (96). 
 
Madhi et al, in study in SA between 1997 and 1999, showed a high burden of GBS (3 per 
1000 live births) that contributed to RDS and neonatal sepsis (97). Contrary to the study by 
Tochie et al in Cameroon, Madhi et al showed that PROM was associated with an increase 
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incidence of RDS and neonatal sepsis (97). Since then, antibiotics have been introduced as 
routine management for patients with PROM and IOL is advocated if labour does not occur 
within 24 hours. This could possibly decrease the incidence of RDS and a study at Chris Hani 
Baragwanath Academic Hospital is currently being conducted to assess the incidence of GBS 
in neonates.  
 
2.9 Maternal outcomes 
 
The primary concern of IOL is uterine rupture (66).  This occurs in 7 per 10 000 women and 
most commonly in those induced with a previous c/s scar (incidence 20-80 per 10 000) (66). 
In a population based study over 4 decades in Norway by Al-Zirqi et al, the incidence of 
uterine rupture in an unscarred uterus was 0.5 per 10 000 (66). Uterine rupture was more 
likely to occur in patients that were induced or augmented (P<0.001). Combination inductions 
(PGs and oxytocin with or without amniotomy) showed the highest risk of uterine rupture 
followed by PGs alone. Uterine ruptures in an unscarred uterus have been limited to case 
reports (98).  
 
Postpartum haemorrhage is defined as blood loss of greater than 500ml at vaginal delivery 
and greater than 1000ml at c/s (99). There is controversy around this definition as it is 
difficult to quantify blood loss objectively (99). The definition now includes clinical 
deterioration as well as clinical shock that may be individualized to each patient (100). Most 
studies show no increased rate of PPH with IOL (101, 102). Hofmeyr et al also showed that 
IOL had no significant impact on PPH or maternal adverse events (90).  A large secondary 
analytical study by Levine et al, which included 863 women, showed that PPH was 
significantly increased in women who were induced compared to spontaneous labour (10% vs 
3%, p=0.001) thus differing from other studies (29). 
 
Induction of labour has a very low incidence of rupture in an unscarred uterus. Larger studies 
are needed to establish the risk of PPH with IOL (66, 90). !
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3 PROBLEM STATEMENT !
Induction of labour is a global topic of discussion with the aim of sourcing an agent that is 
suitable for the patient profile seen in a particular area. In a low resource setting, where there 
is a lack of beds, high numbers of c/s (compared to the resources available) and lack of staff 
(compared to the number of patients seen), an “ideal” inducing agent should be sought. This 
agent should expedite time to delivery and decrease the rate of c/s, thus shortening the length 
of hospital stay with minimal maternal and fetal adverse outcomes.  
 
The pharmacological agents for IOL used at RMMCH are oral misoprostol and vaginal 
dinoprostone. Doses used at RMMCH differ from that of other studies. Oral misoprostol is 
given at 20ug two hourly for 12 doses per cycle over a 24-hour period and dinoprostone one 
milligram six hourly is used (four doses over a 24 hour period). Patients are given the first 
cycle of either agent for a 24 hour period followed by a rest period of 24 hours. If 
spontaneous labour does not occur, a second cycle is given. If spontaneous labour does not 
occur after the second cycle this is considered a failed IOL and a c/s is planned.  
 
A RCT was conducted with large numbers at RMMCH, 16 years ago (103). Since, there has 
been a change in patient profiles with an increase in patient numbers as well as a wider 
spectrum of disease entities. The RCT was also a study done under trial conditions (protocols 
given within an envelope of which the patient was randomized to) whereas this study is one of 
real life clinical situations and practice. !
This study aims to compare the outcomes of oral misoprostol versus vaginal dinoprostone for 
IOL in a low resource setting. !!  
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4 OBJECTIVES OF THIS STUDY 
 
Primary 
 
1. To assess labour processes and mode of delivery 
 
Secondary  
 
1. To compare patient demographics and characteristics 
2. To compare the incidence of maternal and fetal complications 
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5 METHODS !
5.1 Study design !
This was a prospective cross-sectional descriptive study. This involved analysis of the clinical 
history, course of labour, delivery methods and neonatal outcome from patient files.  
 
5.2 Study population !
The study included all women who underwent IOL; with singleton live pregnancies, greater 
than 34 weeks gestational age or more than 2kgs estimated fetal weight. 
 
5.3 Drug selection 
 
Patients were administered either oral misoprostol or vaginal dinoprostone depending on the 
preference of the attending clinical unit of the patient.  
 
5.4 Setting !
Rahima Moosa Mother and Child hospital is a regional academic hospital complex, together 
with Helen Joseph Academic hospital, situated in Newclare, Johannesburg (Figure 5.1, 
Region C). Approximately 700 NVDs and 400 c/s deliveries are performed each month and 
these include both low risk and high risk pregnancies. Rahima Moosa Mother and Child 
Hospital serves a population of approximately 200 000 people draining from Regions A, B 
and C (Figure 5.1). The population is urban and mostly low to middle-income, thus most are 
dependent on state health care services. Rahima Moosa Mother and Child Hospital receives 
referrals from two midwife obstetric units (MOU’s): Discoverers and Diepsloot. As there are 
no secondary hospitals within the region, all high risk pregnant women are referred to 
RMMCH. 
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Figure 5.1 Map of the seven regions in Johannesburg 
 
Within the antenatal ward, inductions are conducted in a separate room consisting of 4 beds. 
This is usually for low risk pregnancies. Inductions also take place in the high care area for 
high risk patients (severe pre-eclampsia, eclampsia). Patients requiring continuous fetal 
monitoring are induced in the labour ward area. This ensures that fetal monitoring is 
performed more frequently and these patients are assessed regularly throughout the induction 
process. 
 
Rahima Moosa Mother and Child Hospital adhere to protocols regarding IOL, which have 
been drawn up by the Department of Obstetrics and Gynaecology of the University of the 
Witwatersrand (104). This serves as a guide within the department.  
• If the Bishop score is less than seven, a cervical ripening agent, either oral misoprostol 
or dinoprostone, is used. 
• If the Bishop score is more than seven, amniotomy with oxytocin infusion is used.  
An algorithm for the use of misoprostol is drawn up in the protocol book (Appendix A). 
Dinoprostone is administered six hourly intravaginally at a dose of one milligram. Up to four 
doses per cycle are given. 
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5.5 Inclusion Criteria 
• Hypertensive disorders of pregnancy (gestational HT, pre-eclampsia, imminent 
eclampsia) 
• Other medical disorders in pregnancy (epilepsy, GDM, overt diabetes mellitus, cardiac 
diseases, antiphospholipid syndrome, thromboembolic disease) 
• Bishop score < seven 
 
5.6 Exclusion Criteria 
• All pregnancies <34 weeks gestation or estimated fetal weight <2kgs 
• Previous c/s or uterine surgery 
• Grand multiparous women (≥ parity of five) 
• Multiple pregnancy 
• Eclampsia 
• Congenital abnormalities of the fetus incompatible with life  
• Intrauterine fetal death 
 
5.7 Sample size !
All patients that were induced who met inclusion criteria during the period from 01 January 
2016 to 30 April 2016 were included in the study. The study intended to include 100 patients, 
50 patients in the misoprostol group and 50 patients in the dinoprostone group. During 
analysis of the results, 5 patients were excluded as both drugs were used in each patient and 
this would cause a bias. A total 95 patients were included, 46 patients in the misoprostol 
group and 49 patients in the dinoprostone group.  
 
5.8 Data Collection !
Patients in the induction room were reviewed every second morning at 07h00 as the 
researcher had clinical duties to attend to and this was the time available for data collection. 
Written informed consent was obtained from those who had met inclusion criteria whilst the 
patients were in the antenatal ward. Information regarding demographics, antenatal care, 
comorbidities and choice of induction agent was collected at this point. Post delivery, patients 
were followed up in the postnatal wards and information regarding their labour and delivery 
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was collected. If the patients were discharged before the researcher was able to retrieve the 
remaining information, the files were retrieved from the records department. If no consent 
was obtained from the patient antenatally, the patient was excluded from the study. Patients 
were located by using the maternity register that is kept in the labour ward and high care area 
department. 
 
All data was captured on a data sheet (Appendix B). 
 
5.8.1 Data collection categories  !
Data were collected under the following categories (Appendix B): 
• Maternal demographics 
• Indications for IOL 
• Labour processes 
• Method of delivery 
• Fetal complications 
• Maternal complications 
 
5.9 Data analysis 
 
Data was captured using Redcap and exported to Microsoft excel. Stata 11 was used for 
statistical analysis. Continuous data were tested for normality. Where applicable the data are 
presented as means and standard deviations. Categorical data are presented as proportions and 
frequencies. The Chi-squared test was used to assess the relationship between categorical 
variables. A 95% confidence interval was used to analyze all data. 
5.10 Ethics  
 
The study received approval from the University of the Witwatersrand’s Human Research 
Ethics Committee, approval number M151126 (Appendix C). 
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6 RESULTS    !
There were a total of 4143 deliveries from 01 January 2016 to 30 April 2016. A total number 
of 200 inductions were conducted during this time of which 107 patients met the inclusion 
criteria for the study. There were seven patients that were excluded due to missing files or 
consent was not obtained. There were 50 patients in the misoprostol group and 50 patients in 
the dinoprostone group. During analysis of the results, five patients were excluded to 
minimize bias. These five patients required a second cycle of IOL with a different drug to the 
first. A total of 49 patients were included in the dinoprostone group and 46 patients in the 
misoprostol group.!
 
6.1 Maternal Characteristics  
 
Table 6.1 Maternal Demographics 
 
Variable Dinoprostone 
Median (range) 
Number (%) 
n=49 
Misoprostol 
Median(range) 
Number (%) 
n= 46 
P value 
Age 28 (18-41) 28 (18-43) 0.70 
BMI 31.3 (23.2-45.7) 33 (23.2-46.7) 0.74 
Parity 1 (0-3) 1 (0-3) 0.74 
Gravidity  3 (1-6) 2 (1-4) 0.53 
Gestational age (GA) 40 (35-43) 38.5 (34-42) 0.04 
Method of 
determination 
of GA 
LNMP 22 (44.9) 26 (56.5)  
0.10 EUS 9 (18.4) 7 (15.2) 
LUS 18 (36.7) 13 (28.3) 
 
The maternal characteristics are described in Table 6.1. The mean age of the whole group of 
patients was 28.49 (n=95) with a standard deviation of 5.73. This was equivalent in both 
groups separately with no statistical significance. The median BMI for the dinoprostone and 
misoprostol groups was 31.3 and 33 respectively (p=0.74); 41.1% of patients were obese. 
Gestational age was determined by three methods: LNMP, early ultrasound (done before 23 
weeks) and late ultrasound (done after 23 weeks). It is not routine for every patient to have an 
ultrasound at the local clinics, as these clinics are not equipped to offer ultrasounds. Majority 
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of the patients’ gestational ages were determined using their LNMP: 44.9% in the 
dinoprostone group and 56.5% in the misoprostol group. There was no statistical significance 
when comparing LNMP, EUS or LUS as a method for determination of gestational age 
between the two groups (p=0.10).  
 
Table 6.2 Indications for the induction of labour   
 
Indication for 
induction  
Dinoprostone 
Number of patients (%) 
n=49 
Misoprostol 
Number of patients (%) 
n=46 
P value 
Post term 25 (51) 15 (32.6) 0.03 
PROM 0 12 (26.1) <0.001 
HT 9 (18.4) 9 (19.6) 0.44 
Medical  8 (16.3) 3 (6.5) 0.07 
IUGR 1 (2) 1 (2.2) 0.48 
Other 6 (12.3) 6 (13) 0.45 
 
Table 6.2 shows the different indications for which these patients were induced. There was a 
statistical difference in the indications for induction of labour between the dinoprostone and 
misoprostol groups  (p<0.001). This was statistically significant for post term pregnancy and 
PROM (p 0.03 and p <0.001 respectively). The most common indication for induction was 
post term pregnancy, followed by HT and PROM. Fifty-one percent of patients were induced 
for post term pregnancy in the dinoprostone group and 32.6% of patients were induced for 
post term pregnancy in the misoprostol group. Dinoprostone was the drug commonly used for 
HT and medical disorders. Misoprostol was the drug of choice for patients with PROM. Table 
6.3 illustrates the other indications for IOL. 
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Table 6.3 Other indications for IOL 
 
Indication  Dinoprostone 
n=6 
Misoprostol  
n=6 
Poor obstetric history  4 1 
Previous IUFD or stillbirth at term  2 0 
Decreased fetal movements at term  0 1 
Big baby  0 1 
Oligohydramnios  0 1 
Chorioamnionitis  0 1 
Fetus with supraventricular tachycardia  0 1 
 
6.2 Labour findings  
 
Table 6.4 Findings of the labour process  
 
Variable Dinoprostone  
Mean ±SD 
Median(range) 
Number (%) 
n=49 
Misoprostol 
Mean ±SD 
Median(range) 
Number (%) 
n= 46 
P value 
Total number of doses of 
each drug 
2 (1-7) 7 (3-24) 0.06 
Labour initiated 47 (96) 37 (80) 0.03 
Time from 
induction to  
onset of labour 
n 47 37  
0.37 Time 
(hours) 
13 (2-87.5) 14 (6-90) 
Duration of labour 8.9 ± 7.2 12.1 ± 10.4 0.10 
Time from induction to 
delivery (hours) 
20.5 (4.5-92) 25 (9-144) 0.18 
Analgesia 25 25 0.84 
 
Table 6.4 illustrates the findings of labour related to the induction process. The Bishop score 
was used to assess cervical favourability prior to induction. The median Bishop score was 
three in the dinoprostone group and four in the misoprostol group (p=0.46). The first stage of 
labour was initiated in 96% patients in the dinoprostone group and 80% in the misoprostol 
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group which was statistically significant (p=0.03). However this did not impact on the 
duration of labour or the time to delivery in the dinoprostone or misoprostol groups. 
Augmentation with an oxytocin infusion was used in 31% of patients in the dinoprostone 
group and 28% in the misoprostol group with no statistical significance (p=0.49). 
 
 
 
  
 
 
Figure 6.1 Distribution of the number of cycles of induction agents 
 
Figure 6.1 is a representation of the number of cycles patients required in each group. In the 
dinoprostone group, 4% of patients required a second cycle and 20% in the misoprostol group 
(p=0.02).  
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6.3 Delivery Methods  
 
Table 6.5 Mode of delivery  
 
Variable  Dinoprostone 
Number (%)  
n=49 
Misoprostol 
Number (%) 
n=46 
Labour initiated 47 (96) 37 (80) 
NVD 33 (67.3) 25 (54.3) 
Caesarean section  16 (32.7) 20 (43.5) 
Assisted delivery 0 1 (2.2) 
 
Table 6.5 shows the mode of delivery within the two induction groups. More patients 
delivered by NVD in the dinoprostone group as compared to the misoprostol group overall 
(67.3% and 56.5% respectively). In a subgroup analysis of the patients who actually went into 
labour in each group, 70.21% of patients delivered NVD in the dinoprostone group and 
70.27% patients in the misoprostol group. Of those that went into labour, there was no 
statistical significance in the rate of NVD between the 2 groups.  
 
Misoprostol had a higher c/s rate overall. In the subgroup analysis, 14 of the 16 c/s (87.5%) in 
the dinoprostone group were performed on patients in established labour. In the misoprostol 
group, 11 of the 20 c/s (55%) were performed on patients in established labour. Therefore 
more c/s were performed in the misoprostol group for failed IOL than the dinoprostone group.  
 
There was no statistical significance in the mode of delivery between the two groups 
(p=0.19). The one assisted delivery (2.2%) was a vacuum delivery on a patient with a 
prolonged second stage due to poor maternal effort. 
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Table 6.6 Indications for Caesarean section  
 
Variable Dinoprostone  
Number (%) 
n=16 
Misoprostol 
Number (%) 
n=20 
Fetal distress 6 (37.5) 7 (35) 
Failed IOL 2 (12.5) 6 (30) 
CPD 5 (31.3) 3 (15) 
Poor progress 2 (12.5) 2 (10) 
Other 1 (6.2) 2 (10) 
 
Table 6.6 demonstrates the indications for the c/s in each induction group. The Chi coefficient 
for the two groups was 2.34 with a p value of 0.51 with no statistical significance. The most 
common indication for c/s was fetal distress: 37.5% in the dinoprostone group and 35% in the 
misoprostol group. No patients had developed antepartum haemorrhage or uterine rupture. 
The time to c/s from the time of booking in the dinoprostone group had a median of 4.25 
hours with a range of 0.5 to 17.2 hours. In the misoprostol group, the median time from 
booking to the c/s taking place was 5.2 hours with a range of 1 to 35 hours. Patients whom the 
indication for c/s was failed IOL, waited for more than 10 hours for a c/s. In the misoprostol 
group, one patient waited for 25 hours and the other for 35 hours. The two patients in the 
dinoprostone group with failed IOL waited 14 and 17 hours respectively for the c/s to take 
place. Other indications in the dinoprostone group included a c/s for failed augmentation of 
labour and other indications in the misoprostol group were for a breech presentation and a 
failed augmentation of labour.  
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6.4 Neonatal outcomes 
 
Table 6.7 Neonatal outcomes  
 
Variable Dinoprostone 
Median(range) 
Number (%) 
n=49 
Misoprostol 
Median(range) 
Number (%) 
n=46 
P value 
Neonatal 
outcome 
Alive 
 
49 (100) 
 
46 (100) 
 
1 
Apgar at 5 minute 10 (8-10) 10 (9-10) 0.44  
Weight (grams) 3160 (2270-4670) 2973 (2085-4565) 0.10  
NICU admission 0  2 (4.3) 0.23  
Neonatal complication 6 (12.2) 9 (19.6) 0.40  
Type of 
complication 
TTN 
RDS 
MAS 
Other 
1 (16.7) 
3 (50) 
0 
2 (33.3) 
5 (55.6) 
1 (11.1) 
0 
3 (33.3) 
0.10 
0.62 
 
0.67 
 
Table 6.7 focuses on the neonatal outcomes. There were no stillbirths in either group. Two 
neonates required NICU admission in the misoprostol group for congenital pneumonia and 
respiratory distress syndrome requiring mechanical ventilation. Complications developed in 
12.2% of neonates in the dinoprostone group and 19.6% in the misoprostol group although 
this was not statistically significant (p=0.40). In those neonates who did develop a 
complication (15 out of 95), 66.67% were respiratory in nature. In the misoprostol group 
55.6% of neonates developed TTN and 50% in the dinoprostone group developed RDS. Two 
neonates in the dinoprostone group developed neonatal jaundice and a persistent 
hypoglycemia and three neonates in the misoprostol group developed neonatal jaundice, 
congenital pneumonia and one neonate presented with a supraventricular tachycardia. The 
diagnosis of the supraventricular tachycardia was made antenatally. 
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6.5 Maternal outcomes  
 
Table 6.8 Maternal complications intrapartum and postpartum  
 
Variable Dinoprostone 
Number (%) 
n=49 
Misoprostol 
Number (%) 
n=46 
p-value 
Maternal complication 7 (14.3) 6 (13) 0.55 
Type of 
complication 
Uterine Rupture 
PPH 
Assisted delivery 
Chorioamnionitis 
Other 
0 
1 (14.3) 
0 
1 (14.3) 
5 (71.4) 
0 
0 
1 (16.7) 
2 (33.3) 
3 (50) 
 
0.52 
0.48 
0.48 
0.39 
 
Table 6.8 describes the maternal complications that occurred during labour, delivery and 
postpartum.  The rates of complications were similar between the dinoprostone and 
misoprostol groups. There were no patients who developed a uterine rupture. The patient who 
developed a PPH in the dinoprostone group was due to a cervical laceration post NVD. One 
patient in the dinoprostone group developed a urinary tract infection post operatively, three 
patients had lower segment tears into the uterine artery during c/s (not significant to cause a 
PPH) and one patient had a delayed second stage due to inadequate contractions. In the 
misoprostol group one patient had intraoperative bleeding due to a friable uterus (this was not 
significant enough to result in a PPH), one patient had retained products of conception post 
NVD requiring an evacuation of the uterus in theatre and one patient had a lower segment tear 
intraoperative. 
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7 DISCUSSION 
 
This study aimed to find the ideal induction agent for a low resource setting. The study 
showed no statistical significance between dinoprostone and oral misoprostol, however 
dinoprostone had a lower c/s rate, a shorter duration of labour and required fewer doses to be 
administered compared to oral misoprostol.  This differed to other studies that showed that 
misoprostol resulted in fewer c/s sections but agreed that misoprostol may have a slower 
induction time (79, 82, 89). 
 
7.1 Maternal characteristics 
 
There was minimal heterogeneity between the characteristics of the patients’ in the 
dinoprostone and misoprostol groups. The mean maternal age of all the patients collectively 
in the study (n=95) was 28.49 years and the mean age in each group was 28 years. This was in 
keeping with other studies where the average age was between 26 -28 years old (29, 35, 79, 
91).  
 
The median parity was one in each group. Grand multiparous women were excluded as this is 
a contraindication to IOL according to the Wits protocol (104). Levine et al showed that 
regardless of parity, IOL had an increase c/s rate when compared to spontaneous labour (29). 
Our study had no control group of patients in spontaneous labour to compare the process of 
IOL as our study compared dinoprostone to misoprostol. 
 
From the 95 patients in our study, 40 patients (41.1%) were obese among the women being 
induced. This is in keeping with the SA statistics for obese pregnant women (32). Obesity in 
pregnancy is associated with PPH and macrosomia (34). In our study, only one patient 
developed a PPH. This patient’s BMI was 25.71 and the neonate weighed 2935g. A cervical 
laceration accounted for the PPH. Of the five patients that had lower segment tears and 
intraoperative bleeding, four were obese. This blood loss was not classified as a PPH in 
patient records. Two of the four patients’ had macrosomic babies (4670g and 4565g). 
Measurement of blood loss intraoperative is subjective and there may have been an 
underestimation of the blood loss during delivery (100). There may be a correlation between 
maternal obesity, c/s rate, PPH and macrosomia, however this is a small study sample size 
and a definitive association between these variables cannot be made. 
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The LNMP was the most common method of determining the gestational age. This may have 
caused inaccuracy in determining the true gestational age as approximately only 50% of 
patients remember the date of their LNMP accurately (105).  Ultrasound in the first trimester 
up to 14 weeks gestational age is the most accurate method of determining the gestational age 
(105).Where a first trimester ultrasound is unavailable, clinical judgement can be of use in 
dating a pregnancy by combining the LNMP with the size of the uterus or height of fundus in 
a singleton pregnancy (40). Patients who did have an early ultrasound in our study either had 
this performed in the private health care sector or were referred to a tertiary institute for a 
high risk pregnancy. Primary health care centers are not routinely well resourced with trained 
sonographers or clinicians and ultrasound machines to perform early ultrasounds on patients.  
 
The method of using LNMP to determine gestational age may have led to inaccuracy in 
dating the pregnancies as post term and thus the higher incidence of post term pregnancy in 
our study. In our study, 42% of patients were induced for post term pregnancy, thus being the 
most common indication for IOL. This is higher than the incidence of post term pregnancies 
in other developed and developing countries: 22.3% in the UK, 21% in Pakistan, 13% in New 
South Wales and 7% in the USA (35, 39-41). The higher incidence of post term pregnancy in 
our study is possibly due to dating of GA by LNMP in 50.53% of patients’ in our study, as for 
these patients’ LNMP was the only option for dating the pregnancy. Ensuring ultrasound 
biometry for dating, even in those patients’ who book late, would reduce the number of 
inaccurate post term inductions (42). 
 
In our study there was a higher number of inductions for post term pregnancy in the 
dinoprostone group (51%) versus the misoprostol group (32.6%). This was due to the method 
of IOL chosen by the attending clinical units. All patients with PROM were induced only 
with misoprostol (26.1%) as the Wits protocol favours the use of misoprostol for patients with 
PROM (104). During the literature analysis, oral misoprostol was shown to be superior to 
dinoprostone in patients with PROM as oral misoprostol resulted in more vaginal deliveries 
compared to dinoprostone (52, 56-58, 106). The efficacy of vaginal drugs decreased as these 
drugs may disembogue with the draining of amniotic fluid and therefore oral misoprostol was 
more effective than dinoprostone (52, 56-58). Oral misoprostol has also shown to decrease 
maternal and neonatal sepsis compared to vaginal dinoprostone in patients with PROM (56, 
58).  
 
 
! 40!
Patients at RMMCH with PROM are induced 24 hours after the rupture of membranes if 
spontaneous labour does not occur (104). Prelabour rupture of membranes increases the risks 
of maternal and fetal sepsis, umbilical cord compression and placental abruption (50, 52). Due 
to these risks, IOL is preferred in comparison to conservative management (52). From the 95 
patients, one patient that was induced for PROM developed a chorioamnionitis and had a c/s 
for fetal distress.  Our study had a low incidence of complications from PROM as these 
patients were actively managed by inducing labour after 24 hours from the rupture of 
membranes if spontaneous labour did not occur. 
 
Due to the lack of screening for GBS in SA, all patients with PROM for more than 24 hours 
received antibiotics including penicillin (53, 54, 104). One patient was induced for a 
suspected chorioamnionitis based on an irritable uterus on clinical examination; there was no 
malodorous liquor upon delivery and both mother and neonate were healthy with no 
complications. This could have been a case of a subclinical chorioamnionitis.   
 
Diabetic patients were induced with dinoprostone: 16.3% in the dinoprostone group and 2.2% 
in the misoprostol group. This was due to the diabetic unit at RMMCH using dinoprostone as 
their induction agent of choice due to preference of the Head of unit. There is insufficient 
evidence on which induction agent is superior in diabetic patients.  
 
7.2. Labour findings 
 
In this study, the median Bishop score was three in the dinoprostone group and four in the 
misoprostol group with no statistical significance. Patients with a ‘ score of greater than seven 
are augmented with oxytocin and not a cervical ripening agent (104). This is in keeping with 
studies showing that the higher the Bishop score, the higher the likelihood of a NVD (9). 
Most studies excluded women with a Bishop score of greater than six and some greater than 
eight, which was dependent upon the institution protocol (79, 90, 91). The range of medians 
in these studies was between four and five. In our study, the median Bishop score was lower 
than that of the studies in the literature. This may be due to lower parity. The possibility of 
pregnancies labeled as “post term” (which may not have been the case due to dating with 
LNMP in most of our patients) may have contributed to the lower bishop scores in our study. 
This was not clinically significant as the Bishop score was still classified as being 
unfavourable. However, as in the Tygerberg study, even ultrasounds beyond 23 weeks have 
been shown to be more accurate in dating the pregnancy compared to LNMP and clinical 
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methods, hence this policy should be adopted in our institute (42). This may reduce the 
number of inductions for post term pregnancy.  
 
Labour was successfully initiated in 96% of women in the dinoprostone group and 80% in the 
misoprostol group. This was statistically significant (p=0.03). This correlates to the number of 
failed inductions of 4% in the dinoprostone group and 13% in the misoprostol group in our 
study. This difference in patients in whom labour was successfully initiated may seem to be 
due to the fact that the dinoprostone group had a higher number of inductions for post term 
pregnancy; however there was no difference in the bishop score between the two groups. 
Thus a definitive reason for the higher number of patients in whom labour was initiated in the 
dinoprostone group cannot be determined.  Many studies focused on c/s rate and failure to 
achieve vaginal delivery within 24 hours rather than if labour was successfully initiated, or 
the incidence of failed induction (79, 82, 90). One study by Moodley et al, showed a rate of 
failed induction of 5.7% in the dinoprostone group and 6% in the misoprostol group, however 
failed IOL was defined as not having achieved labour within 24 hours from the time of 
induction (91). In our study failed IOL is defined as not achieving established labour after 
administration of two cycles of an inducing agent. The second cycle of induction meant that 
after the first cycle of 24 hours, the patient would rest for 24 hours and then start another 
cycle of the same inducing agent for a repeated 24 hours. 
 
At RMMCH in this study, labour was more frequently initiated with dinoprostone than 
misoprostol. Despite this finding being statistically significant, there was no impact in the 
time from induction to the onset of labour, the overall duration of labour or the time from 
induction to delivery. This was in keeping with literature around the globe (77, 82). Our study 
differed to that of Alfirevic et al that showed women induced with misoprostol were more 
likely to achieve vaginal delivery within 24 hours compared to dinoprostone; however, there 
was marked heterogeneity between the studies compared by Alfirevic et al (82, 89). 
 
Fifty percent of patients in the dinoprostone group and 50% of patients in the misoprostol 
group received analgesia, at least in one form. Overall, 10% of patients who received 
analgesia received an epidural with the remainder 90% receiving an opioid in the form of 
pethidine 100mg intramuscularly six hourly. In order to counteract the nausea and vomiting, 
metoclopramide is given concurrently. The literature describes a rate of epidural analgesia of 
approximately 31-32% (84-86). These are quoted rates in first world countries. One study by 
Davey et al showed that 52% of women who were induced or had labour that was augmented 
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received an epidural compared to 18% of those who had spontaneous labour (88). In a local 
study by Matonhodze et al at RMMCH, analgesia rates ranged from 26-37% in patients’ that 
were induced and thus have improved over the last 15 years in our study.  
 
Since January 2016, the Anaesthetic Department at RMMCH provides a 24 hour epidural 
service. A higher rate of epidural analgesia is expected and further studies would be able to 
ascertain this to compare rates after the implementation of a 24-hour service. In a study in 
Nigeria by Enabor et al, 51 % of patients believed that inducing labour would inflict more 
pain (107). Most women in labour should be receiving analgesia and this leaves room for 
improvement at RMMCH, as only 50% of labouring women receive any form of analgesia 
(83). The low rate of women receiving analgesia may be attributed to patient, staff and 
resources. Patients’ do not request analgesia and midwives may not administer analgesia due 
to the high patient load. The lack of skills of the health care workers administering epidural 
analgesia, the lack of monitoring equipment and drugs all contribute to a low rate of 
administration of analgesia.  
 
In our study, 2% of patients required a second cycle of induction in the dinoprostone group 
and 13% in the misoprostol group. Most studies reviewed in the literature did not mention the 
number of cycles required (77, 79, 82, 90, 91). It is therefore difficult to measure our study 
against international centres. One study by Malende et al in KZN showed that 15% of patients 
induced with oral misoprostol required a second cycle of IOL, in keeping with the findings of 
our study (92). !
7.3 Delivery methods 
 
In our study more patients delivered vaginally in the dinoprostone group than the misoprostol 
group even though this was not statistically significant. Dinoprostone had a c/s rate of 32.3% 
and misoprostol had a c/s rate of 43.5%. Studies by Alfirevic et al and Matonhodze et al both 
showed an increase in c/s rate with dinoprostone (79, 89). This may be due to the higher doses 
of dinoprostone used in these studies. The SOGC guideline showed that misoprostol was 
more effective than dinoprostone in achieving vaginal delivery (4). Moodley et al showed no 
difference in c/s rate between misoprostol and dinoprostone (91). The same doses used in our 
study were also used by Moodley et al, hence the congruency in results. However, in the 
subgroup analysis of those patients in whom labour was initiated, there was no difference in 
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the NVD rate between the dinoprostone and misoprostol group (70.21% and 70.27% 
respectively). More c/s were performed for failed IOL in the misoprostol group.  
 
Despite no statistical significance in the c/s rate between dinoprostone and misoprostol in our 
study, this has marked clinical significance. The difference in the c/s rate between 
dinoprostone and misoprostol was 10.8%. This increase in number of c/s in the misoprostol 
group means that these patients had a longer hospital stay, thus increasing costs and had 
exposure to an invasive surgical procedure that is associated with an increase in morbidity and 
mortality (88). At RMMCH, a patient who has an uncomplicated c/s stays in hospital for two 
days post c/s and is monitored by a doctor each day. A patient, who delivers vaginally and has 
no complications, is discharged six hours post delivery. Some patients are discharged the next 
day, during daylight hours, as it is not safe to discharge patients at night due to lack of 
transport facilities. The midwives monitor, discharge these patients and alert the doctor on 
call shoul complications arise. Therefore an increase in c/s rate in the misoprostol group 
increased the burden of patients to the doctors, nursing staff and hospital system in an already 
patient overloaded environment. 
 
The most common indication for c/s in the dinoprostone and misoprostol groups was fetal 
distress (37.5% and 35% respectively). Dinoprostone had a decreased c/s rate for failed IOL 
compared to misoprostol (12.5% and 30% respectively). All doses of misoprostol were given 
two hourly, and the mixture prepared in a dark bottle to maintain thermal stability at room 
temperature. However if the bottles were not thoroughly mixed before administration, the 
patient would simply be consuming water or not receive the recommended 20ug dose. This 
may have attributed to incorrect administration and thus an increased rate of failed IOL in the 
oral misoprostol group.  The ACOG stated that uterine tachysystole with or without fetal heart 
rate changes occurs more frequently in women induced with misoprostol compared to 
dinoprostone (8). In our study uterine hyperstimulation is not discussed as this is not routinely 
documented in patient files and therefore could not be analyzed. Cardiotocographic traces 
were misplaced from patient files and these were not analyzed. The researcher was not 
present at each delivery to assess these aspects. Bernardes et al showed that fetal distress was 
the commonest indication for c/s in patients’ induced, but this was a subgroup analysis of the 
HYPITAT and DIGITAT trials, therefore these patients were already compromised due to 
medical conditions and these maternal comorbidities were the actual cause of the fetal distress 
(75).  
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Two large systematic reviews also showed that oral misoprostol reduced the likelihood of c/s 
(76, 82). In studies done in SA, Matonhodze et al and Hofmeyr et al showed an increased rate 
of fetal distress in the dinoprostone group compared to the misoprostol group (79, 90). 
Moodley et al showed similar rates of fetal distress in both groups with no statistical 
significance (91). Malende et al showed that fetal distress was the most common indication 
for c/s after IOL, followed by cephalopelvic disproportion and failed IOL (92).  
 
In comparison, our study differed in that dinoprostone and misoprostol had similar rates of c/s 
for fetal distress. This may be attributed to the small study sample size. Misoprostol resulted 
in a larger number of patients requiring a c/s for failed IOL. Patients with failed IOL waited a 
long time for c/s (up to 35 hours). Therefore misoprostol contributed to a longer hospital stay 
and increased costs were incurred due to this.  
7.4 Neonatal outcomes 
 
Fetuses with congenital abnormalities and intrauterine fetal deaths were excluded in our 
study, as this would skew data on neonatal outcomes. 
 
Most studies showed no difference in neonatal outcomes between dinoprostone and 
misoprostol (79, 82, 90, 91). These studies mainly commented on mortality, NICU admission, 
Apgar at five minutes and MAS. Moodley et al showed that MAS occurred in 8.2% of 
neonates in the dinoprostone group and 10.9% in the misoprostol group, but this was not 
statistically significant (91). 
 
In our study the neonatal complications were respiratory in nature, RDS and TTN, rather than 
MAS. This could be due to the small study sample size and the overall rare occurrence of 
these complications. The higher incidence of RDS and TTN may be attributed to 26% of 
patients induced for PROM in keeping with the study by Madhi et al (97). Congenital 
pneumonia was diagnosed in two neonates, but whether this was due to GBS or another 
organism is unknown. Our study showed no significant difference in neonatal outcomes. 
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7.5 Maternal outcomes 
 
Maternal complication rates were similar in the dinoprostone and misoprostol groups in this 
study: 14.3% in the dinoprostone group and 13% in the misoprostol group. In keeping with 
literature, there were no cases of uterine rupture as the incidence of uterine rupture in an 
unscarred uterus is low: 0.5 per 10 000 deliveries (98). Of the 13 patients who developed 
complications, one patient had a PPH. This was a patient, in the dinoprostone group, who 
sustained a cervical laceration intrapartum. This patient was induced for gestational diabetes 
mellitus and delivered a 2935g neonate. The laceration most likely occurred from the patient 
prematurely bearing down, as it was noted in the patient’s file that the patient was restless, 
uncooperative and bearing down when she was in the first stage of labour. Lower segment 
tears at c/s occurred in three patients in the dinoprostone group and one patient in the oral 
misoprostol group. The blood loss from these tears were not classified as a PPH as the 
patients were haemodynamically stable, but there could be a margin of error as the estimated 
blood loss is a subjective measure.  
 
Levine et al showed an increase in PPH among women who had IOL compared to 
spontaneous labour (29). Matonhodze et al showed no cases of uterine rupture and similar 
rates of PPH to our study, which was also in keeping with the findings of other studies (79, 
90-92).  
 
In our study, despite no statistical significance in maternal complication rates, the sample size 
was too small to comment adequately on maternal complication rates. 
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8 LIMITATIONS 
 
• The study sample size was small to adequately comment on neonatal and maternal 
complications, especially that of MAS and uterine rupture.  
• There was a selection bias of the drugs used in our study. The choice of the drug 
depended on the individual unit the patient was admitted to. The diabetic unit 
preferred the use of dinoprostone; therefore all diabetic patients were induced with 
dinoprostone only.  
• There may have been interobserver differences in determining the Bishop score as 
patients are assessed by health care workers of different levels of experience: intern 
doctors, medical officers, registrars in training and specialist consultants. However 
this was unlikely to have significantly influenced the study. 
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9 CONCLUSION 
 
Since the advent of IOL, many methods have been studied in women with different antenatal 
disorders in an attempt to reduce maternal and neonatal morbidity and mortality.  
 
This study attempted to compare the outcomes of vaginal dinoprostone and oral misoprostol 
at RMMCH. Labour was initiated in more patients in the dinoprostone group and 
dinoprostone resulted in fewer c/s than misoprostol, however this was not statistically 
significant. There was no difference in neonatal and maternal outcomes. 
 
The use of dinoprostone or misoprostol is therefore equally effective in our setting. A larger 
study or RCT is recommended to adequately assess neonatal and maternal complication rates.  
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